Simplify Life with Omnipod® 5
Omnipod 5 automatically adjusts your insulin delivery every 5 minutes without tubes or manual guesswork. It's the first and only tubeless Automated Insulin Delivery System (AID) system that integrates with leading sensor brands, for people living with type 1 diabetes, aged 2 and above.
What makes Omnipod 5 different?
Omnipod 5 helps automate insulin delivery day and night, with just 3 simple parts working together in a continuous loop:
- The Pod
- A compatible sensor*
- The Omnipod 5 Controller.
Pod shown without the necessary adhesive. Screen for illustrative purposes only.
*Sensor sold separately and requires a separate prescription.
To view compatible sensors, visit: https://www.omnipod.com/en-au/what-is-omnipod/omnipod-5/sensors
“Omnipod 5 is the #1 pump among all new pump users.3”
Meet the Omnipod 5 System
The Pod
- Tubeless, wearable, waterproof†
- Small enough to be worn under clothing
- Sits comfortably on the body for up to 3 days (72 hours)
- Automatically adjusts insulin delivery using the Omnipod 5 Algorithm
- No tubes. No Multiple Daily injections. No daily hassle.
The Controller
Your handheld Omnipod 5 Controller connects via Bluetooth® for discreet, wireless control.
The Sensor
Your choice of sensor continuously sends glucose values to the Pod for real-time insights without routine finger pricks.‡
The Pod and sensor need to be in ‘line of sight’ to stay in Automated Mode.
Proven to help you stay in range1,2
Omnipod 5 is designed to help keep your glucose levels steadier throughout the day and night by automatically adjusting insulin delivery.
What this means for you:
Shown to increase Time in Range1,2
Over 80% Time in Range with optimised settings4
Helps protect from lows
In a real-world setting, Omnipod 5 users spent 1% time in hypoglycaemia5
Helps correct highs
Adults and adolescents on Omnipod 5 experienced a 46% reduction of time in hypoglycaemia6
Why people choose Omnipod 5
Omnipod 5 helps you spend more time living life and less time thinking about diabetes. Unlike other insulin pumps, Omnipod 5 requires no tubing and can be worn discreetly under clothing.
Tubeless and waterproof†
No tubes, no tangles. Wear your Pod in the shower, swimming pool or sea!†
Automated insulin delivery
Adjusts insulin delivery every 5 minutes, so you don't have to.
No more multiple daily injections
It can replace over a thousand injections a year.7
Start your journey with Omnipod® 5
Take the first step toward tubeless, automated insulin delivery. Whether you want to try it, see it, or speak with someone about it, you’ll find the option that suits you best.
Features that make everyday life easier
SmartBolus Calculator and Custom Foods: simplify mealtime math
The SmartBolus Calculator uses your sensor glucose value and trend to calculate insulin doses. Custom Foods builds on this by letting you save up to 50 meals, foods, or snacks you eat often. Together, they reduce the need for complex calculations and make repeat meals, kids’ lunches, and busy days quicker and easier to manage.
Activity Feature: support when life gets active
When enabled, our Activity feature reduces insulin delivery when glucose typically goes low, like when exercising.
- exercise
- sleepovers
- sick days
- times when you simply want gentler insulin delivery
Here’s what our Podders have to say about Omnipod® 5:
I did used to worry about going hypo in front of my kids or my family or friends. It was like always on my mind. And then I decided to give the Omnipod 5 a go. This thing is like epically cool.
Richard
Podder® since 2024
Omnipod 5 has allowed us to give Priya the freedom that all kids deserve, whilst not compromising her safety or worrying about disconnecting her from her insulin delivery
Kimmie – Mother of Priya
Podder® since 2023
At first, I told myself, “I’ll give it a go. If it doesn’t work out, I can always go back to pens.” But from the first few weeks, I realised how much mental space it freed up”
Sevanah
Podder® since 2024
Ready to take the next step?
You’ve seen what Omnipod® 5 can do, now choose how you’d like to begin. Whether you want a hands-on trial, expert guidance, or a live walkthrough, we’re here to help you get started with confidence.
†The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller is not waterproof.
‡Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs 29.7%, P<0.0001, respectively. Mean time in hypoglycaemic range in adults/adolescents (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3- mo Omnipod 5 = 1.32%, P<0.0001. Mean time in hypoglycaemic range in children (<3.9 mmol/L or <70mg/dL as measured by CGM): ST = 2.21%, 3-mo Omnipod 5 = 1.78%, P<0.0456.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3- month AID phase with Omnipod 5 system. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9mmol/L or <70mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, P<0.0001.
3. Omnipod was the most frequently chosen pump in the past year among people new to an insulin pump in survey conducted by dQ&A across Europe (n=3646), the United States (n=6,148) H2/Q4 2024 - dQ&A H2 2024 Diabetes Patient Voice EU p. 61, dQ&A Q4 2024 Diabetes Patient Voice US p. 44
4. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.
5. Forlenza G, et al. Diabetes Technol Ther. 2024. 26(8):514-525. Retrospective analysis of real-world data from 69,902 individuals with type 1 diabetes using Omnipod 5 had a median time below range (<3.9 mmol/L or <70 mg/dL) of 0.97%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
6. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D, including 128 participants aged 14-70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in hypoglycaemic range (<3.9 mmol/L or <70mg/dL as measured by CGM; 12AM - < 6AM) as measured by CGM: ST: 2.07% vs. Omnipod 5: 0.82%, P<0.0001 Comparison is a relative change. Study funded by Insulet
7. Chiang et al. Diabetes Care. 2014:37:2034-2054. 1,643 insulin injections in a year based on people with type 1 diabetes on multiple daily injections taking ≥ 3 bolus and 1-2 basal injections/day (~4.5/day).
8. Insulet Data on File. OP5-003 Clinical Study Report. 2024. A 13-week randomised controlled trial conducted among 194 adults (age 18-70 years) with type 1 diabetes in France and the U.S., comparing the safety and effectiveness of the Omnipod 5 Automated Insulin Delivery (AID) System versus conventional non-AID pump therapy and CGM (control). At 13-weeks of Omnipod 5 use 130 participants were asked via a System Usability Survey (SUS) if the system was easy to use. 71.5% of participants strongly agreed and 19.2% agreed.
9. 2025 Customer Survey of U.S. adults with Type 1 diabetes (n=1230), 92% agreed Omnipod 5 gives them peace of mind
10. 2025 Customer Survey of U.S. adults with Type 1 diabetes, n=1230, 90% agreed bolusing with Omnipod 5 is as quick as sending a text